Dr. Ryan J. Malone, M.D.

Medicare patients and services

Medicare patients, 2024

699

Services billed

29,699

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 26 companies reported 280 payments worth $40,978 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Indiana →

Industry-funded research

Named as a principal investigator on 20 industry-funded studies in 2025, from 7 companies. The companies reported $2,658,909 in research payments for these studies, mostly to the institutions running them.

• A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
  Pfizer Inc.
• A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
  Janssen Research & Development, LLC
• A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
  Janssen Research & Development, LLC
• A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
  Janssen Research & Development, LLC
• A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
  Janssen Research & Development, LLC
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
  Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232
• BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned
  Bayer HealthCare Pharmaceuticals Inc.
• ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
  Ferring Pharmaceuticals As · Terminated · NCT06026332
• A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Pros…
  Janssen Research & Development, LLC
• A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
  Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Urology clinicians in Jeffersonville

• James L. Bailen, MD
• Bradley B. Bell, MD
• William C. Buschemeyer JR., M.D.
• John B. Eifler JR., M.D.
• Michael A. Goedde
• Charles J. Goodwin, M.D.
• Graham R. Hale, MD
• John H. Jurige JR., M.D.